Page 168 WHO - Guidelines on the pharmacological treatment of persisting pain in children with medical illness

prolonged-release morphine S
(Recommendation 9) 43–44, 90–91, 146
routine opioid rotation SC 7
(Recommendation 12) 44–45, 91–92, 146 SCD 7
strategy for breakthrough pain scope (of the guidelines)
(Recommendation 17) 46, 93–94, 147 beyond scope 13
switching of opioids Scoping document for the WHO treatment guidelines
(Recommendation 10) 44–45, 91–92, 146 for chronic pain in children 83
switching of route of administration selective serotonin reuptake inhibitors 96–97
(Recommendation 10) 44–45, 91–92, 146 acronym 7
two-step strategy neuropathic pain 51, 96–97, 147
(Recommendation 1) 38, 84–85, 146 sickle cell disease 25
use of paracetamol and ibuprofen in mild acronym 7
pain (Recommendation 2) 38, 86–87, 146 episodic pain, multidimensional assessment 33
use of strong opioids in moderate and severe oral versus intravenous morphine, GRADE table 119
pain (Recommendation 4) 42, 87–88, 146 pain 13
rectal administration episodic (acute) pain 25
alternative route 40 persisting pain in ~ 25
unreliable bioavailability 40 sickle cell anaemia 25
references 148 vaso-occlusive episodes 25
regulations 42, 55 side-effects: see adverse effects
regulatory authorities 13 Single Convention on Narcotic Drugs 131
regulatory barriers 56 domestic manufacture 134–135
rescue doses 46 medical and scientific purposes 132
research agenda 53, 60, 129 prescibing/dispensing opioids
breakthrough pain requirements 138
immediate-release morphine versus other SSRI 7
opioids, routes of administration, clinical Steering Group on Pain Treatment Guidelines 142
question 93–94 strategy for breakthrough pain (Rec. 17)
Resolution 2005/25 55 46, 94, 147
Resolution 58.22 55 strong opioids
resources saved by treating pain 58 distribution 137
right to be spared avoidable pain 55 subcutaneous
right to health 55 acronym 7
United Nations Convention on the Rights of alternative route 40
the Child 55 substance misuse, avoidance 61, 131
WHO Constitution 55 supply barriers 56
route of administration 40 switching of opioids (Rec. 10) 44–45, 91–92, 146
alternative routes 45, 92, 146 switching of route of administration (Rec. 10)
intramuscular route 40, 45, 92, 146 44–45, 91–92, 146
intranasal 45, 92–93
intravenous 46, 92–93 T
oral administration recommended 40, 45, 92–93, 146
alternative routes if oral not available 40, 92–93 tailoring treatment to the individual 37, 146
oral route versus alternative routes (clinical targeted audience 13
question) 92–93 task shifting 59, 101, 147
rectal 40, 92 education, pain management 101, 147
subcutaneous 40, 45, 92–93 evidence 101
continuous infusion 45 licensing requirements, opioids 101, 147
indwelling catheter 45 regulatory environment, enabling 60
switching 44–45, 91, 146 task shifting prescription, administration of
inadequate analgesic effect 44–45, 91, 146 opioids from doctors to other health professionals,
intolerable side-effects 44–45, 91, 146 health system question 101, 123–124
transdermal 40, 92 TCA 7
routine opioid rotation (Rec. 12) 44–45, 91, 146 in neuropathic pain 147
use as adjuvant medication, clinical
question 96–97
three-step ladder 37, 39, 84
clinical question 84
codeine 39
codeine, use 39
tramadol, use 39

165 <